Program
Midodrine
Also written as “Midodrine HCl Tablets 5 mg”, “Midodrine HCl” and “Dexmedetomidine and Midodrine”.
Its studies are mostly in Hypotension, Orthostatic · Alzheimer Disease · Hypotension, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 50 open or running | phase 4since Sep 20, 2002 | Sep 20, 2002 | none ahead |
| Viatris | 30 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Applied Cognition | 10 open or running | phase 2since Feb 15, 2026 | Feb 15, 2026 | none ahead |
| Nimedical | 10 open or running | phase 4since Feb 8, 2017 | Feb 8, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 20, 2002First studies: 2 phase 4 studies in Hypotension, OrthostaticNew to TakedaTakeda · NCT00046163, NCT00046475
- Nov 8, 2007Phase 4 study in Hypotension, OrthostaticTakeda · NCT00555880 · 24 enrolled · United States
- Mar 30, 2008Viatris's first studies: 3 phase 1 studies in HealthyNew to ViatrisViatris · NCT00650364, NCT00650013, NCT00648440
- Jan 18, 20122 phase 4 studiesTakeda · NCT01518946, NCT01515865
- Feb 8, 2017Nimedical's first study: phase 4 study in Intradialytic HypotensionNew to NimedicalNimedical · NCT03080441 · 35 enrolled
- Feb 15, 2026Applied Cognition's first study: phase 2 study in Alzheimer DiseaseNew to Applied CognitionApplied Cognition · NCT07432997 · 31 enrolled · United States
TargetBeta
“Adrenergic receptor alpha-1 agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tamsulosinrule | Boehringer Ingelheim | phase 4 | 60 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| Prazosinrule | Pfizer | phase 3 | 4 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07432997Alzheimer Disease · United States | 2 | Completed | Applied Cognition | Sep 13, 2024 | 31 |
| NCT03080441Intradialytic Hypotension | 4 | UNKNOWN | Nimedical | Apr 1, 2017 | 35 |
| NCT01518946Hypotension, Orthostatic · United States | 4 | Completed | Takeda | Jun 22, 2013 | 24 |
| NCT01515865Symptomatic Orthostatic Hypotension · United States, Czechia, Poland and more | 4 | Completed | Takeda | Nov 11, 2013 | 98 |
| NCT00650364Healthy · United States | 1 | Completed | Viatris | Aug 2002 | 38 |
| NCT00650013Healthy · United States | 1 | Completed | Viatris | Aug 2002 | 23 |
| NCT00648440Healthy · United States | 1 | Completed | Viatris | Nov 2002 | 36 |
| NCT00555880Hypotension, Orthostatic · United States | 4 | Completed | Takeda | Mar 21, 2005 | 24 |
| NCT00046475Hypotension, Orthostatic · United States | 4 | Completed | Takeda | Nov 24, 1999 | 140 |
| NCT00046163Hypotension, Orthostatic · United States | 4 | Terminated | Takeda | Aug 6, 2003 | 150 |
How it is read
Names in the registry
- “Midodrine HCl Tablets 5 mg”, 3 entries
- “Midodrine HCl”, 2 entries
- “Dexmedetomidine and Midodrine”, 1 entry
- “midodrine hydrochloride (ProAmatine®)”, 1 entry
- “Midodrine hydrochloride”, 1 entry
Conditions, from the studies’ own filings
- Hypotension, Orthostatic, 5 studies
- Alzheimer Disease, 1 study
- Hypotension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.